CGN Logo



CGN enters into collaboration with Novo Nordisk to generate data on STARNET.


CGN signs agreement with Mount Sinai on license agreement to the Beat-IT technology.


Clinical Gene Networks AB is a SME in the EU-project, CVD@target financed within the 7th frame program. CGN will perform data analysis to evaluate genetic markers associated with coronary artery disease. Leading scientists of genome-wide association studies (GWAS) in Germany and United Kingdom are other partners in this project.


Prof. Eric E Schadt becomes major shareholder and board member of CGN. Dr Schadt's belief in CGN:s unique biobanks and datasets is a key motivation for his increased engagement in CGN something the board of directors warmly welcome. "The last 2-3 years have been tough for CGN, Eric's recognition of CGN:s business concept to build predictive disease models from clinical gene networks is therefore particular important" say newly elected chair of the board, Johan Björkegren.


CGN:s CEO since 9 years, Johan Björkegren today announces his retirement. "The growth of CGN now requires a full-time CEO that can take recent success of the company's network-based drug-discovery pipeline to collaborations with the pharmaceutical industry" says Björkegren who will remain on the board and provide support for the new CEO who is currently being recruited. Björkegren's choice of time point for his retirement relates to his parallel commitment as a full-time researcher at the Karolinska Institutet. In the overlapping period, operative matters will be handled by the board.


CGN:s board member Johan Björkegren and CGN:s adviser Prof. Eric E Schadt at Mount Sinai School of Medicine (MSSM), New York publish a perspective in the new Science journal focusing on translational medicine (i.e. Science Translational Medicine). The article discuss the promising outlooks of the NEW (Network Enabled Wisdom) biology to reveal disease risk and thereby mechanisms by which complex disease like CAD and MI evolve. This perspective highlights CGNs strategy applying a network-based drug and diagnostic discovery pipeline to develop personalized CAD and MI therapies in the coming decade. “Network identification for the benefits of the patients”. (NEW (Network-enabled wisdom) in Biology, Medicine and Heath Care, Schadt EE, Björkegren LM. J. Science Translational Medicine, Februrary 4th, 2012).


CGN files an application to Eurostar program to seek funds for evaluating recently discovered drug candidates acting against a "hub"-regulator in a CAD network controlling leukocyte migration across the endothelium in coronary atherosclerosis. The evaluation of the application will take place during the fall 2011.


Eric Schadt, PhD, Director of the Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Science at Mount Sinai School of Medicine joins the Advisory Board of Clinical Gene Networks.


CGN issues new shares for current stock holders and for other strategically important Investors.


CGN get SEK 1 million in support from the Swedish investment agency ALMI in Stockholm to develop in silico and in vitro drug evaluation platforms.


CGN receives SEK 3.5 million from the EU, FP6-2005-Life Science -Health-6 as programa SME partner to the PROCARDIS application.


CGN has been selected to present at the Nordic Venture Summit, Copenhagen, Radisson SAS Scandinavia Hotel, 9 October 2006.


CGN participates as one of 30 invited technology companies all categories at the Innovation and Technology conference arranges by STING (Stockholm Innovation and Growth).


The CEO of CGN, Johan Björkegren raises a debate on “Internet-based healthcare in Sweden” in the January 11th issue of Sweden's largest daily business paper, "Dagens Industri".


CGN completes design and evaluation of an algorithm to directly from whole-genome expression data detect highly-regulated genes ("hubs") in gene networks applicable for mammalian systems.


CGN applies to EU FP6STREP project as a small to middle sized enterprise (SME) together with the PROCARDIS Consortium (PRecOcious Coronary ARtery DISease – PROCARDIS). The PROCARDIS team is dedicated to discovery of novel susceptibility genes for precocious coronary artery disease. Today more than 10 000 patients including affected and unaffected siblings have been screened. Positional cloning has been performed using 400 markers throughout the genome. PROCARDIS consists of 5 academic partners from UK, Germany, Italy and Sweden and one major industrial partner, AstraZeneca.


CGNhas together with 10 other Swedish biotech companies (such as Active Biotech, Anamar and Arexis) been invited to a private summit with selected prominent American biotech investors. The Swedish American life science summit will take place in Stockholm, August 23-25. The Summit provides a high level platform for idea exchange and development of new business opportunities between the leading life science investors and companies in Sweden, and the United States.


CGN is one of the winners in the Swedish Business Development Agency, Vinnova’s yearly search for the 20 most promising start-up companies in Sweden. CGN is awarded SEK 300 000.


CGN is featured in the June issue of Biotech Sweden, the largest Nordic biotech newspaper.


CGN has developed three novel network algorithms. One machine learning algorithm for reliable detection of biomarkers from high-dimensional data. The second algorithm enables rational compound evaluation from gene expression data.The third algorithm is a probabilistic algorithm for identification of localnetworks from seed genes.


Professor Håkan Eriksson at Karolinska Institutet is new chairman of the board of directors. Peter Lindgren is appointed to the board of directors.


AtheroCode database version 1is completed. More than 750 million data points ranging from clinical characteristics to human and mouse gene expression data related to atherosclerosis has been stored in this database. The AtheroCode database will serve as the backbone to dismantle gene network in atherosclerosis.


Professor Jim Collins at the Department of Biomedical Engineering at Boston University agrees to join Clinical Gene Networks advisory board. Dr. Collins is the leading scientist in the emerging field of network biology. He is also the co-director and co-founder of the Center for BioDynamics at BU. His research is published in Nature, Science, PNAS on a regular basis. Dr. Collins has won a number of awards, including a Rhodes Scholarship and in 2003 the MacArthur Fellowship commonly known as "genius award".


Professor Aldons J Lusis at the Microbiology, Immunology, and Molecular Genetics Department at UCLA agrees to join Clinical Gene Networks advisory board. Dr. Lusis is the leading scientist in the field of atherosclerosis research.


Clinical Gene Networks gets early access to Affymetrix 100k or 500k Human SNPs arrays. 300 GeneChip Human Genome U133 Plus 2.0 Array measurements of total RNA isolated from tissues relevant to atherosclerosis together with 100 mouse GeneChip© Mouse Expression Set 430 are completed.


Clinical Gene Networks completes 200 GeneChip Human Genome U133 Plus 2.0 Array measurements of total RNA isolated from tissues relevant to atherosclerosis.


Clinical Gene Networks agrees on commercial license to use the Cre-Lox system with Bristol-Myers Squibb.


Clinical Gene Networks and Karolinska Institutet in agreement with Affymetrix Inc. regarding use of, and early access to the GeneChip© technology.


Founder and Professor Johan Björkegren publishes article in Sweden's second largest daily newspaper - Svenska Dagbladet, in the leader column "Brännpunkt" -on the feasibility of whole-genome based clinical research in Sweden.


Clinical Gene Networks is granted SEK 580 000 from the Swedish Business Development Agency, NUTEK for technology and business development. CGN co-founder, Professor Tegnér, publishes a paper in Proceeding of the National Academy of Sciences on computational modeling of dynamical biological networks.


Clinical Gene Networks hires 2 PhD-students for technology development with the support from the Centre of Medical Innovation at the Karolinska Institutet


Clinical Gene Networks technology development issupported bythe Foundation of Strategic Research with SEK 0.9 million


Peter Lindgren is recruited as acting Chief Financial Officer.


Clinical Gene Networks AB is incorporated.


The "Stockholm Atherosclerosis Gene Expression" ("STAGE") Study gets financial support from AstraZeneca, Mölndal.


Clinical Gene Networks is supported by Karolinska Innovation AB at the Karolinska Institutet.